MAXCYTE INC DL-,01

At MaxCyte’s annual meeting, Patrick Balthrop, Cynthia Collins and Stanley Erck were elected as Class II directors. Shareholders confirmed CohnReznick LLP as the independent auditor for the fiscal year ending December 31, 2026. MaxCyte reported strong Q1 results, beat earnings and revenue forecasts, and again meets the Nasdaq minimum bid-price requirement, but despite a strong balance sheet it still has negative EBITDA and a 27% YTD share-price decline. » Więcej na de.investing.com

MaxCyte reported Q4 2025 revenue of $7.3 million and EPS of -$0.09, missing analysts’ expectations of $9.36 million and -$0.08. Full‑year revenue fell to $33 million from $38.6 million a year earlier, and core revenue growth remained weak. Gross margin improved to 78 percent and operating expenses declined by 12 percent; the company is debt‑free and expects a cash position of at least $136 million at the end of 2026. MaxCyte is banking on the new ExPERT‑DTx platform to drive revenue growth from the second half of 2026, but remains exposed to customer concentration and market uncertainties. » Więcej na de.investing.com

MaxCyte received a notice from NASDAQ because its stock closed below $1.00 for 30 consecutive trading days, failing to meet the minimum price requirement under Rule 5450(a)(1). The listing remains in place for now; the company has until September 14, 2026 to regain compliance by posting a closing bid of $1.00 or higher for at least 10 consecutive trading days. If the requirements are not met, NASDAQ may grant an additional compliance period with a possible transfer to the Nasdaq Capital Market or a potential delisting, against which MaxCyte can file an appeal. » Więcej na de.investing.com